Akero Therapeutics (Nasdaq: AKRO), a clinical-stage company developing treatments for patients with metabolic diseases, in its pending $5.2 billion sale to Novo Nordisk (NYSE: NVO).
3G Capital in connection with the $8 billion financing for its acquisition of Skechers (NYSE: SKX).
Scorpion Therapeutics in its $2.5 billion pending sale of the PI3Kα inhibitor program, a treatment for breast cancers in clinical trials, to Eli Lilly and Company (NYSE: LLY).
